Receipt date: 05/31/2007 10597926 - GAU: 1648

Sheet 1 of 2

011000 1 01 2				
Substitute for form 1449/PTO, based on PTO/SB/08A and 08B	Application Number	10/597,926		
	Filing Date	08/11/2006		
INFORMATION DISCLOSURE	First Named Inventor	Ensoli et al.		
STATEMENT BY APPLICANT	Art Unit	1648		
	Examiner Name	Not Assigned		
	Attorney Docket Number	114-06		

Confirmation No. 7925

GWS 5/31/2007

U.S. PATENT DOCUMENTS

	Cite	D	Dublication Data		Pages, Columns, Lines, Where Relevant Passages or
Examiner Initial*	1 4	Document Number (US-)	Publication Date (MM-DD-YYYY)	Name	Relevant Figures Appear
IIIIIai	No.'	Number (03-)	(101101-00-1111)	Name	(or entire document unless
					noted otherwise)

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No. ¹	Foreign Patent Document Number (include WIPO country code)	Publication Date (MM-DD-YYYY)	Name	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear (or entire document unless noted otherwise)	T ²
	1	WO 2005/039631	05/06/2005	Caputo et al.		
	2	WO 02/080917	10/17/2002	Engstrand et al.		
	3	WO 01/54719	08/02/2001	Voss		
	4	JP 2003277262	10/02/2003	Kanji		
	5	JP 2001286284	10/16/2001	Sato et al.		
	6	EP 1431306	06/23/2004	Bussolino et al.		
	7	EP 0567643	11/03/1993	Kawakita et al.		

NON-PATENT LITERATURE DOCUMENTS

Examiner Initial*	Cite No. ¹	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	8	Gzyl et al. (Jan. 2004) "Effect of Partial and Complete Variable Loop Deletions of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein on the Breadth of gp160-Specific Immune Responses," <i>Virology</i> 318(2):493-506	
	9	Lee et al. (Apr. 2, 1999) "Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct bu Overlapping Structures Involved in Chemokine and Coreceptor Function," J. Biol. Chem. 274(14):9617-9626	
	10	O'Brien et al. (May 1996) "Anti-Human Immunodeficiency Virus Type 1 Activity of an Oligocationic Compound Mediated Via gp120 V3 Interactions," <i>J. Virol.</i> 70(5):2825-2831	

Examiner Signature	/Nicole Kinsey/	Date Considered	04/08/2009
-----------------------	-----------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here or "x" if English language Translation is attached.

Receipt date: 05/31/2007 10597926 - GAU: 1648

Sheet 2 of 2

Substitute for form 1449/PTO, based on PTO/SB/08A and 08B	Application Number	10/597,926
	Filing Date	08/11/2006
INFORMATION DISCLOSURE	First Named Inventor	Ensoli et al.
STATEMENT BY APPLICANT	Art Unit	1648
	Examiner Name	Not Assigned
	Attorney Docket Number	114-06

Confirmation No. 7925 GWS 5/31/2007

Examiner Initial*	Cite No. ¹	REFERENCE Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	Penman et al. (1993) "Omeprazole Inhibits Colorectal Carcinogenesis Induced by Azoxymethane in Rats," <i>Gut</i> 34:1559-1565	
	12	Sartippour et al. (2003) "The Effect of Commonly Used Drugs on Angiogenesis," Anticancer Res. 23:231-234	
	13	Wyatt et al. (1995) "Involvement of the V1/V2 Variable Loop Structure in the Exposure of Human Immunodeficiency Virus Type 1 gp120 Epitopes Induced by Receptor Binding," <i>J. Virol.</i> 69:5723-5733	

Examiner	/Nicole Kinsey/	Date	04/08/2009
Signature	/record remody/	Considered	0 1, 0 0

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional).
²Applicant is to place a check mark here or "x" if English language Translation is attached.